|
Course Information
|
Back to Catalog
|
This lesson is supported by:
|
Provided by:
Keys to Successful Management of Agitation and Aggression in the Elderly:
When and How to Treat Patients with Behavioral Disturbances
After completing this program, participants will be able to:
- Examine clinical data on successful management of behavioral disturbances in older patients through both behavioral and pharmacological interventions, differentiating which behaviors respond best to which types of interventions.
- Compare and contrast pharmacologic treatments for older adults considering patient safety, efficacy profiles, drug-drug interactions, ease of dosing, and drug regimen simplification.
- Discuss the direction of research and treatment of behavioral disturbances and dementia in older patients including new findings on the neuroprotective effects of psychotropic agents and the long-term effects of treatment.
Target Audience
Pharmacists
Faculty
Program Chair
Manju Beier, PharmD, FASCP
Senior Partner, Geriatric Consultant Resources, LLC
Clinical Associate Professor of Pharmacy, The University of Michigan
Ann Arbor, MI
Disclosure: Consultant for: Abbott, Bristol-Myers Squibb, Forest; Speakers Bureau/Receive Honoraria from: Abbott, Bristol-Myers Squibb, Forest, Janssen, Pfizer
Jeffrey L. Cummings, MD
Director, UCLA Alzheimer’s Disease Center
The Augustus S. Rose Professor of Neurology
Professor of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine
Los Angeles, CA
Disclosure: Consultant for: AstraZeneca, Aventis, Best Practice Consulting, Biomedisyn, Council of Advisors, Eisai, Eli Lilly, Genentech, Myriad, Neurochem, Neurotrax, Novartis, Ono, Pfizer, and Praecis. Grant/Research Support: Eisa and Pfizer.
J. Craig Nelson, MD
Leon J. Epstein MD Chair in Geriatric Psychiatry
Director of Geriatric Psychiatry, University of California San Francisco
San Francisco, CA
Disclosure: Consultant for: Abbott, Biovail, Bristol-Myers Squibb, Corcept, Eli Lilly, GlaxoSmithKline, Orexigen, Organon, Pfizer, Sepracor and Shire. Speakers Bureau/Receive Honoraria: Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Organon, Pfizer and Wyeth. Grant/Research Support: Eli Lilly, Forset and Pfizer.
|
|
|
|
|
|
|
Technologies Used
|
|
|
 Macromedia Flash
|
|
|
|
Price: FREE!
|
|
ACPE Accreditation
|
|
ABcomm, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This home study web activity has been assigned a maximum of 1.25 credit hours (0.125 CEU) and the ACPE UPN: 811-000-06-003-H01.
Expiration Date: 12/15/2009
|
| |
To receive educational credit, participants must complete an online evaluation form and pass the online assessment with a score of 70% or better. If you do not receive a minimum score of 70% or better, you are permitted 1000 retake(s). After passing the assessment, you can view, print and track your statements of credit online. There is no fee to participate in this activity.
|
|
|
The material presented here does not reflect the views of Pharmacy Choice, Inc., RxSchool, or the companies providing educational content. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
|
This lesson is supported by:
|
|
|
